Modulation of AMPK/ TET2/ 5-hmC axis in response to metabolic alterations as a novel pathway for obesity-related colorectal cancer development

Wogonin Inhibits Ovarian Cancer by Activating the AMPK-TET2-5hmC Axis

Ovarian cancer is one of the most common gynecologic cancers. In the quest for effective anti-cancer agents, this study explores the effects of wogonin, a naturally occurring flavonoid, on the viability and migration of A2780 and Kuramochi ovarian cancer cells. A2780 and Kuramochi human ovarian cancer cell lines were utilized. Cytotoxicity and migration were evaluated using the CCK8 assay and the wound-healing assay, respectively. The effect of wogonin on the growth of A2780 ovarian cancer cells in vivo was assessed using a nude mouse model. The phosphorylation and half-life of AMPK were determined by western blot analysis. The level of 5hmC was assessed using dot blot analysis. The impact of wogonin on gene expression was examined through RNA-Seq. Our results show that wogonin not only impedes cancer cell growth and mobility both in vitro and in vivo but also significantly increases the cytotoxicity of cisplatin. Investigations of the mechanism underlying these effects reveal that wogonin suppresses genes associated with cell proliferation and the EMT and upregulates metabolic pathways, particularly the AMPK signaling pathway, which is crucial for increasing 5hmC levels. These results indicate that wogonin promotes DNA demethylation by stabilizing TET2. In conclusion, our findings highlight not only the therapeutic potential of wogonin but also its preventative capability against ovarian cancer in individuals with metabolic disorders, such as diabetes, who are at increased risk of ovarian cancer.

The role of TET2 in solid tumors and its therapeutic potential: a comprehensive review

Indeed, tumors are a significant health concern worldwide, and understanding the underlying mechanisms of tumor development is crucial for effective prevention and treatment. Epigenetics, which refers to changes in gene expression that are not caused by alterations in the DNA sequence itself, plays a critical role in the entire process of tumor development. It goes without saying that the effect of methylation on tumors is a significant aspect of epigenetics. Among the methylation modifications, DNA methylation is an important part, which plays a regulatory role in tumor-related genes. Ten-eleven translocation 2 (TET2) is a highly influential protein involved in the modification of DNA methylation. Its primary role is associated with the suppression of tumor development, making it a significant player in cancer research. However, TET2 is frequently mentioned in hematological diseases, its role in solid tumors has received little attention. Studying the changes of TET2 in solid tumors and the regulatory mechanism will facilitate its investigation as a clinical target for targeted therapy and may also provide directions for clinical treatment of malignant tumors.